{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:11:13Z","timestamp":1792548673464,"version":"4.5.0"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Liver fibrosis has been proposed as the most important predictive indicator affecting prognosis of patients with chronic liver disease. It is defined by an abnormal accumulation of extracellular matrix components that results from necrotic and inflammatory processes and eventually impairs organ function. With no approved therapy, comprehensive cellular models directly derived from patient\u2019s cells are necessary to understand the mechanisms behind fibrosis and the response to anti-fibrotic therapies. Primary human cells, human hepatic cell lines and human stem cells-derived hepatic stellate-like cells have been widely used for studying fibrosis pathogenesis. In this paper, we depict the cellular crosstalk and the role of extracellular matrix during fibrosis pathogenesis and summarize different <jats:italic>in vitro<\/jats:italic> models from simple monolayers to multicellular 3D cultures used to gain deeper mechanistic understanding of the disease and the therapeutic response, discussing their major advantages and disadvantages for liver fibrosis modelling.<\/jats:p>","DOI":"10.3389\/fcell.2025.1567916","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:40:46Z","timestamp":1745991646000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Challenges of in vitro modelling of liver fibrosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Patricia","family":"Ros-Tarraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"Villanueva-Badenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"Sanchez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Gallego-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Teresa","family":"Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Tolosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but No other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/labinvest.2016.36","article-title":"Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts","volume":"96","author":"Aoudjehane","year":"2016","journal-title":"Lab. Invest."},{"key":"B3","doi-asserted-by":"publisher","first-page":"100115","DOI":"10.1016\/j.jhepr.2020.100115","article-title":"The liver matrisome - looking beyond collagens","volume":"2","author":"Arteel","year":"2020","journal-title":"JHEP Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.17179\/excli2023-6878","article-title":"Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel","volume":"23","author":"Asadollahi","year":"2024","journal-title":"EXCLI J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/hep.22721","article-title":"Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development","volume":"49","author":"Asahina","year":"2009","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0151736","DOI":"10.1371\/journal.pone.0151736","article-title":"Extracellular matrix molecular remodeling in human liver fibrosis evolution","volume":"11","author":"Baiocchini","year":"2016","journal-title":"PloS one"},{"key":"B7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/liv.12570","article-title":"The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis","volume":"35","author":"Barreyro","year":"2015","journal-title":"Liver Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"key":"B9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10565-020-09544-2","article-title":"Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists","volume":"37","author":"Boeckmans","year":"2021","journal-title":"Cell Biol. Toxicol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/BF02623469","article-title":"Establishment of a continuous cell line from fibrotic schistosomal granulomas in mice livers","volume":"21","author":"Borojevic","year":"1985","journal-title":"Vitro Cell Dev. Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease","volume":"74","author":"Boyer-Diaz","year":"2021","journal-title":"J. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"105728","DOI":"10.1016\/j.tiv.2023.105728","article-title":"3D multi-cell-type liver organoids: a new model of non-alcoholic fatty liver disease for drug safety assessments","volume":"94","author":"Bronsard","year":"2024","journal-title":"Toxicol Vitro"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e10207","DOI":"10.1002\/btm2.10207","article-title":"Biofabricated 3D in vitro model of fibrosis-induced abnormal hepatoblast\/biliary progenitors' expansion of the developing liver","volume":"6","author":"Brovold","year":"2021","journal-title":"Bioeng. Transl. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1002\/bit.27379","article-title":"Differential fibrotic phenotypes of hepatic stellate cells within 3D liver organoids","volume":"117","author":"Brovold","year":"2020","journal-title":"Biotechnol. Bioeng."},{"key":"B15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1089\/ten.2006.12.519","article-title":"The basement membrane component of biologic scaffolds derived from extracellular matrix","volume":"12","author":"Brown","year":"2006","journal-title":"Tissue Eng."},{"key":"B16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3390\/bioengineering8080106","article-title":"Engineering and monitoring 3D cell constructs with time-evolving viscoelasticity for the study of liver fibrosis in vitro","volume":"8","author":"Cacopardo","year":"2021","journal-title":"Bioeng. (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"21387","DOI":"10.1038\/srep21387","article-title":"Stiffening hydrogels for investigating the dynamics of hepatic stellate cell mechanotransduction during myofibroblast activation","volume":"6","author":"Caliari","year":"","journal-title":"Sci. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1039\/c6ib00027d","article-title":"Gradually softening hydrogels for modeling hepatic stellate cell behavior during fibrosis regression","volume":"8","author":"Caliari","year":"","journal-title":"Integr. Biol. (Camb)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0036-1597816","article-title":"Regression of liver fibrosis","volume":"37","author":"Campana","year":"2017","journal-title":"Semin. Liver Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jhep.2024.01.032","article-title":"Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models","volume":"80","author":"Caon","year":"2024","journal-title":"J. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2307673","DOI":"10.1002\/adma.202307673","article-title":"The material world of 3D-bioprinted and microfluidic-chip models of human liver fibrosis","volume":"36","author":"Carvalho","year":"2024","journal-title":"Adv. Mater"},{"key":"B22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/abbs\/gmt143","article-title":"Isolation and culture of hepatic stellate cells from mouse liver","volume":"46","author":"Chang","year":"2014","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.7150\/ijbs.37500","article-title":"Matrix mechanics as regulatory factors and therapeutic targets in hepatic fibrosis","volume":"15","author":"Chen","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1097\/HEP.0000000000000423","article-title":"Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities","volume":"78","author":"Chen","year":"2023","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.stem.2018.05.027","article-title":"Generation of hepatic stellate cells from human pluripotent stem cells enables in vitro modeling of liver fibrosis","volume":"23","author":"Coll","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"120611","DOI":"10.1016\/j.biomaterials.2020.120611","article-title":"3D culture of HepaRG cells in GelMa and its application to bioprinting of a multicellular hepatic model","volume":"269","author":"Cuvellier","year":"2021","journal-title":"Biomaterials"},{"key":"B27","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D'Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"120247","DOI":"10.1016\/j.biomaterials.2020.120247","article-title":"The human liver matrisome - proteomic analysis of native and fibrotic human liver extracellular matrices for organ engineering approaches","volume":"257","author":"Daneshgar","year":"2020","journal-title":"Biomaterials"},{"key":"B29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/intbio\/zyab011","article-title":"Bioengineered 3D electrospun nanofibrous scaffold with human liver cells to study alcoholic liver disease in vitro","volume":"13","author":"Das","year":"2021","journal-title":"Integr. Biol. (Camb)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41598-017-02866-y","article-title":"Liraglutide improves liver microvascular dysfunction in cirrhosis: evidence from translational studies","volume":"7","author":"de Mesquita","year":"2017","journal-title":"Sci. Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature12681","article-title":"Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis","volume":"505","author":"Ding","year":"2014","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13069-015-0031-z","article-title":"In vitro reversion of activated primary human hepatic stellate cells","volume":"8","author":"El Taghdouini","year":"2015","journal-title":"Fibrogenes. Tissue Repair"},{"key":"B35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s43856-022-00209-1","article-title":"Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology","volume":"2","author":"Ewart","year":"2022","journal-title":"Commun. Med. (Lond)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.4049\/jimmunol.1400861","article-title":"IL-17A enhances the expression of profibrotic genes through upregulation of the TGF-beta receptor on hepatic stellate cells in a JNK-dependent manner","volume":"193","author":"Fabre","year":"2014","journal-title":"J. Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1053\/j.gastro.2019.07.036","article-title":"ECM1 prevents activation of transforming growth factor beta, hepatic stellate cells, and fibrogenesis in mice","volume":"157","author":"Fan","year":"2019","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3109\/00498254.2012.728013","article-title":"Preparation and culture of precision-cut organ slices from human and animal","volume":"43","author":"Fisher","year":"2013","journal-title":"Xenobiotica"},{"key":"B39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hep4.1647","article-title":"Human nonalcoholic steatohepatitis on a chip","volume":"5","author":"Freag","year":"2021","journal-title":"Hepatol. Commun."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1074\/jbc.275.4.2247","article-title":"Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury","volume":"275","author":"Friedman","year":"2000","journal-title":"J. Biol. Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1002\/bit.28485","article-title":"Optimization of physical microenvironment to maintain the quiescence of human induced pluripotent stem cell-derived hepatic stellate cells","volume":"120","author":"Gong","year":"2023","journal-title":"Biotechnol. Bioeng."},{"key":"B42","doi-asserted-by":"publisher","first-page":"8157","DOI":"10.1038\/s41598-018-26383-8","article-title":"Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis","volume":"8","author":"Goto","year":"2018","journal-title":"Sci. Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"6138","DOI":"10.1038\/s41467-021-26410-9","article-title":"A human multi-lineage hepatic organoid model for liver fibrosis","volume":"12","author":"Guan","year":"2021","journal-title":"Nat. Commun."},{"key":"B44","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1582-4934.2007.00060.x","article-title":"Immortal hepatic stellate cell lines: useful tools to study hepatic stellate cell biology and function?","volume":"11","author":"Herrmann","year":"2007","journal-title":"J. Cell Mol. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","article-title":"Hepatic stellate cells as key target in liver fibrosis","volume":"121","author":"Higashi","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1056\/NEJMra022296","article-title":"Alport's syndrome, Goodpasture's syndrome, and type IV collagen","volume":"348","author":"Hudson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"12444","DOI":"10.1038\/s41598-017-12691-y","article-title":"Modeling the kinetics of integrin receptor binding to hepatic extracellular matrix proteins","volume":"7","author":"Hudson","year":"2017","journal-title":"Sci. Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3390\/cells9040964","article-title":"Human liver spheroids as a model to study aetiology and treatment of hepatic fibrosis","volume":"9","author":"Hurrell","year":"2020","journal-title":"Cells"},{"key":"B49","doi-asserted-by":"publisher","first-page":"a004903","DOI":"10.1101\/cshperspect.a004903","article-title":"Overview of the matrisome--an inventory of extracellular matrix constituents and functions","volume":"4","author":"Hynes","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1039\/d4bm00874j","article-title":"Amplified response of drug-induced liver fibrosis via immune cell co-culture in a 3D in vitro hepatic fibrosis model","volume":"12","author":"Jung","year":"2024","journal-title":"Biomater. Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: an orally administered, smallmolecule, liver-directed, beta-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"touchREV Endocrinol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/adt.2012.474","article-title":"Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure","volume":"11","author":"Karsdal","year":"2013","journal-title":"Assay. Drug Dev. Technol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.addr.2017.07.014","article-title":"The good and the bad collagens of fibrosis - their role in signaling and organ function","volume":"121","author":"Karsdal","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4254\/wjh.v13.i2.187","article-title":"Adult human liver slice cultures: modelling of liver fibrosis and evaluation of new anti-fibrotic drugs","volume":"13","author":"Kartasheva-Ebertz","year":"2021","journal-title":"World J. Hepatol."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.10.044","article-title":"Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease","author":"Kim","year":"2024","journal-title":"J. Hepatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3748\/wjg.v23.i2.204","article-title":"Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease","volume":"23","author":"Kostrzewski","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1016\/j.stemcr.2021.11.002","article-title":"Development of human iPSC-derived quiescent hepatic stellate cell-like cells for drug discovery and in vitro disease modeling","volume":"16","author":"Koui","year":"2021","journal-title":"Stem Cell Rep."},{"key":"B59","doi-asserted-by":"publisher","first-page":"121006","DOI":"10.1016\/j.biomaterials.2021.121006","article-title":"A fully defined matrix to support a pluripotent stem cell derived multi-cell-liver steatohepatitis and fibrosis model","volume":"276","author":"Kumar","year":"2021","journal-title":"Biomaterials"},{"key":"B60","doi-asserted-by":"publisher","first-page":"7299","DOI":"10.1038\/s41598-019-43759-6","article-title":"Matrix stiffness modulates the activity of MMP-9 and TIMP-1 in hepatic stellate cells to perpetuate fibrosis","volume":"9","author":"Lachowski","year":"2019","journal-title":"Sci. Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.stemcr.2022.09.010","article-title":"Generation of functionally competent hepatic stellate cells from human stem cells to model liver fibrosis in vitro","volume":"17","author":"Lai","year":"2022","journal-title":"Stem Cell Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1021\/acsbiomaterials.9b01735","article-title":"Application of gelatin bioinks and cell-printing technology to enhance cell delivery capability for 3D liver fibrosis-on-a-chip development","volume":"6","author":"Lee","year":"2020","journal-title":"ACS Biomater. Sci. Eng."},{"key":"B63","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bpg.2011.02.005","article-title":"Mechanisms of hepatic fibrogenesis","volume":"25","author":"Lee","year":"2011","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jcmgh.2023.05.010","article-title":"In vivo and in vitro models to study liver fibrosis: mechanisms and limitations","volume":"16","author":"Lee","year":"2023","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2015.11.026","article-title":"Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro","volume":"78","author":"Leite","year":"2016","journal-title":"Biomaterials"},{"key":"B66","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10237-023-01785-4","article-title":"Mechanical properties of human hepatic tissues to develop liver-mimicking phantoms for medical applications","volume":"23","author":"Lemine","year":"2024","journal-title":"Biomech. Model Mechanobiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"G272","DOI":"10.1152\/ajpgi.00379.2019","article-title":"Matrix stiffness and shear stresses modulate hepatocyte functions in a fibrotic liver sinusoidal model","volume":"320","author":"Li","year":"2021","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"814496","DOI":"10.3389\/fmed.2021.814496","article-title":"Liver fibrosis-from mechanisms of injury to modulation of disease","volume":"8","author":"Liedtke","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jep.2005.10.021","article-title":"In vitro protective effects of salvianolic acid B on primary hepatocytes and hepatic stellate cells","volume":"105","author":"Lin","year":"2006","journal-title":"J. Ethnopharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1021\/acsbiomaterials.3c00213","article-title":"Synergistic modulation of a tunable microenvironment to fabricate a liver fibrosis chip for drug testing","volume":"9","author":"Liu","year":"2023","journal-title":"ACS Biomater. Sci. Eng."},{"key":"B71","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s13318-015-0316-z","article-title":"Tolerability and pharmacokinetics of hydronidone, an antifibrotic agent for hepatic fibrosis, after single and multiple doses in healthy subjects: an open-label, randomized, dose-escalating, first-in-human study","volume":"42","author":"Liu","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41419-021-04418-9","article-title":"Matrix stiffness modulates hepatic stellate cell activation into tumor-promoting myofibroblasts via E2F3-dependent signaling and regulates malignant progression","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.clinbiochem.2022.12.012","article-title":"Biomarkers reflecting pericellular fibrosis improve together with liver histology after bariatric surgery in early non-alcoholic fatty liver disease","volume":"113","author":"Lonsmann","year":"2023","journal-title":"Clin. Biochem."},{"key":"B74","doi-asserted-by":"publisher","first-page":"a005058","DOI":"10.1101\/cshperspect.a005058","article-title":"Extracellular matrix degradation and remodeling in development and disease","volume":"3","author":"Lu","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jhep.2016.01.010","article-title":"Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers","volume":"64","author":"Lua","year":"2016","journal-title":"J. Hepatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"120335","DOI":"10.1016\/j.biomaterials.2020.120335","article-title":"The fibrotic response of primary liver spheroids recapitulates in vivo hepatic stellate cell activation","volume":"261","author":"Mannaerts","year":"2020","journal-title":"Biomaterials"},{"key":"B77","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"B78","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jhep.2016.04.018","article-title":"Sinusoidal communication in liver fibrosis and regeneration","volume":"65","author":"Marrone","year":"2016","journal-title":"J. Hepatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/s41467-025-56024-4","article-title":"Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis","volume":"16","author":"Martinez Garcia de la Torre","year":"2025","journal-title":"Nat. Commun."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF01606425","article-title":"The hepatic extracellular matrix. I. Components and distribution in normal liver","volume":"423","author":"Martinez-Hernandez","year":"1993","journal-title":"Virchows Arch. A Pathol. Anat. Histopathol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1136\/gutjnl-2019-318372","article-title":"Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells","volume":"69","author":"Marti-Rodrigo","year":"2020","journal-title":"Gut"},{"key":"B82","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12967-019-1770-1","article-title":"In vitro effects of interleukin (IL)-1 beta inhibition on the epithelial-to-mesenchymal transition (EMT) of renal tubular and hepatic stellate cells","volume":"17","author":"Masola","year":"2019","journal-title":"J. Transl. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"156587","DOI":"10.1016\/j.cyto.2024.156587","article-title":"Dual blockade of interleukin-17A and interleukin-17F as a therapeutic strategy for liver fibrosis: investigating the potential effect and mechanism of brodalumab","volume":"178","author":"Matsuda","year":"2024","journal-title":"Cytokine"},{"key":"B84","doi-asserted-by":"publisher","first-page":"111556","DOI":"10.1016\/j.fct.2020.111556","article-title":"The liver fibrosis niche: novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix","volume":"143","author":"Matsuda","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.addr.2017.05.018","article-title":"Engineering in vitro models of hepatofibrogenesis","volume":"121","author":"Mazza","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1111\/liv.13177","article-title":"Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial","volume":"36","author":"Meissner","year":"2016","journal-title":"Liver Int."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1080\/07853890.2022.2132418","article-title":"The role of hepatic microenvironment in hepatic fibrosis development","volume":"54","author":"Meng","year":"2022","journal-title":"Ann. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-3207-9_1","article-title":"Isolation, purification, and culture of primary murine hepatic stellate cells: an update","volume":"2669","author":"Meurer","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41390-020-01177-9","article-title":"The role of integrins in inflammation and angiogenesis","volume":"89","author":"Mezu-Ndubuisi","year":"2021","journal-title":"Pediatr. Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2007-07-101261","article-title":"Hematopoietic origin of hepatic stellate cells in the adult liver","volume":"111","author":"Miyata","year":"2008","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","first-page":"9827","DOI":"10.1038\/s41598-017-09391-y","article-title":"A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells","volume":"7","author":"Miyauchi","year":"2017","journal-title":"Sci. Rep."},{"key":"B92","doi-asserted-by":"publisher","first-page":"11808","DOI":"10.3389\/jpps.2023.11808","article-title":"Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches","volume":"26","author":"Mohammed","year":"2023","journal-title":"J. Pharm. Pharm. Sci."},{"key":"B93","first-page":"731","article-title":"Establishment of a new human cell line, LI90, exhibiting characteristics of hepatic Ito (fat-storing) cells","volume":"72","author":"Murakami","year":"1995","journal-title":"Lab. Invest."},{"key":"B94","doi-asserted-by":"publisher","first-page":"8536","DOI":"10.1038\/s41598-024-58989-6","article-title":"Development of a high throughput system to screen compounds that revert the activated hepatic stellate cells to a quiescent-like state","volume":"14","author":"Nakano","year":"2024","journal-title":"Sci. Rep."},{"key":"B95","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.bbamcr.2019.01.008","article-title":"Role of AGAP2 in the profibrogenic effects induced by TGF\u03b2 in LX-2 hepatic stellate cells","volume":"1866","author":"Navarro-Corcuera","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.3748\/wjg.v24.i48.5415","article-title":"Role of cenicriviroc in the management of nonalcoholic fatty liver disease","volume":"24","author":"Neokosmidis","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"7666","DOI":"10.3748\/wjg.v23.i43.7666","article-title":"Pathological process of liver sinusoidal endothelial cells in liver diseases","volume":"23","author":"Ni","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"100198","DOI":"10.1016\/j.jhepr.2020.100198","article-title":"Organoids to model liver disease","volume":"3","author":"Nuciforo","year":"2021","journal-title":"JHEP Rep."},{"key":"B99","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3350\/cmh.2020.0187","article-title":"Anti-fibrotic treatments for chronic liver diseases: the present and the future","volume":"27","author":"Odagiri","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1787\/e1f1244b-en","article-title":"Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment OECD series on testing and assessment","volume":"34","year":"2005","journal-title":"OECD Publ."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1787\/9789264304796-en","article-title":"Guidance document on good in vitro method practices (GIVIMP) OECD series on testing and assessment","volume":"286","year":"2018","journal-title":"OECD Publ."},{"key":"B102","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s43152-021-00030-3","article-title":"Extracellular matrix remodeling in chronic liver disease","volume":"2","author":"Ortiz","year":"2021","journal-title":"Curr. Tissue Microenviron. Rep."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/liv.14888","article-title":"Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis","volume":"41","author":"Perakakis","year":"2021","journal-title":"Liver Int."},{"key":"B103","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.addr.2012.03.009","article-title":"Naturally and synthetic smart composite biomaterials for tissue regeneration","volume":"65","author":"Perez","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e0179995","DOI":"10.1371\/journal.pone.0179995","article-title":"Pro-fibrotic compounds induce stellate cell activation, ECM-remodelling and Nrf2 activation in a human 3D-multicellular model of liver fibrosis","volume":"12","author":"Prestigiacomo","year":"2017","journal-title":"PLoS One"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"15566","DOI":"10.1038\/s41598-021-94990-z","article-title":"Photocrosslinkable liver extracellular matrix hydrogels for the generation of 3D liver microenvironment models","volume":"11","author":"Ravichandran","year":"2021","journal-title":"Sci. Rep."},{"key":"B107","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e0153118","DOI":"10.1371\/journal.pone.0153118","article-title":"Characterization of the MMP\/TIMP imbalance and collagen production induced by IL-1\u03b2 or TNF-\u03b1 release from human hepatic stellate cells","volume":"11","author":"Robert","year":"2016","journal-title":"PLoS One"},{"key":"B109","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/cells9040875","article-title":"Liver fibrosis: mechanistic concepts and therapeutic perspectives","volume":"9","author":"Roehlen","year":"2020","journal-title":"Cells"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e2303128","DOI":"10.1002\/advs.202303128","article-title":"Combinatorial microgels for 3D ECM screening and heterogeneous microenvironmental culture of primary human hepatic stellate cells","volume":"11","author":"Ryoo","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"B112","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1247\/csf.28.105","article-title":"Hepatic stellate cells: unique characteristics in cell biology and phenotype","volume":"28","author":"Sato","year":"2003","journal-title":"Cell Struct. Funct."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"B114","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bbrc.2011.07.041","article-title":"Suppression of hepatic stellate cell activation by microRNA-29b","volume":"412","author":"Sekiya","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B115","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1038\/s41467-020-17161-0","article-title":"Mechano-modulatory synthetic niches for liver organoid derivation","volume":"11","author":"Sorrentino","year":"2020","journal-title":"Nat. Commun."},{"key":"B116","doi-asserted-by":"publisher","first-page":"730176","DOI":"10.3389\/fcell.2021.730176","article-title":"Liver fibrosis: therapeutic targets and advances in drug therapy","volume":"9","author":"Tan","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.3390\/cancers13194936","article-title":"Optimization and validation of a novel three-dimensional Co-culture system in decellularized human liver scaffold for the study of liver fibrosis and cancer","volume":"13","author":"Thanapirom","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B118","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jceh.2019.03.002","article-title":"Drug development for nonalcoholic fatty liver disease: landscape and challenges","volume":"9","author":"Thiagarajan","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1038\/s41596-021-00509-1","article-title":"Directed differentiation of human induced pluripotent stem cells to hepatic stellate cells","volume":"16","author":"Vallverdu","year":"2021","journal-title":"Nat. Protoc."},{"key":"B120","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.addr.2017.07.004","article-title":"3D in vitro models of liver fibrosis","volume":"121","author":"van Grunsven","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B121","doi-asserted-by":"publisher","first-page":"e0374","DOI":"10.1097\/HC9.0000000000000374","article-title":"The role of sinusoidal endothelial cells and TIMP1 in the regulation of fibrosis in a novel human liver 3D NASH model","volume":"8","author":"van Riet","year":"2024","journal-title":"Hepatol. Commun."},{"key":"B122","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1007\/s10856-014-5345-7","article-title":"Influence of 3D porous galactose containing PVA\/gelatin hydrogel scaffolds on three-dimensional spheroidal morphology of hepatocytes","volume":"26","author":"Vasanthan","year":"2015","journal-title":"J. Mater Sci. Mater Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"33453","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci. Rep."},{"key":"B124","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"B135","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0022-2275(20)32030-7","article-title":"An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro","volume":"41","author":"Vogel","year":"2000","journal-title":"Journal of lipid research"},{"key":"B125","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.matbio.2018.02.020","article-title":"Therapeutic approaches to control tissue repair and fibrosis: extracellular matrix as a game changer","author":"Walraven","year":"2018","journal-title":"Matrix Biol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"787748","DOI":"10.3389\/fphar.2022.787748","article-title":"Molecular mechanisms and potential new therapeutic drugs for liver fibrosis","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13619-022-00148-1","article-title":"Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids","volume":"12","author":"Wu","year":"2023","journal-title":"Cell Regen."},{"key":"B128","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/gut.2004.042127","article-title":"Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis","volume":"54","author":"Xu","year":"2005","journal-title":"Gut"},{"key":"B129","doi-asserted-by":"publisher","first-page":"7879","DOI":"10.3892\/mmr.2017.7641","article-title":"PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review)","volume":"16","author":"Ying","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s00204-022-03265-7","article-title":"In vitro modeling of liver fibrosis in 3D microtissues using scalable micropatterning system","volume":"96","author":"Zahmatkesh","year":"2022","journal-title":"Arch. Toxicol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11010-006-2677-8","article-title":"De-differentiation of primary human hepatocytes depends on the composition of specialized liver basement membrane","volume":"283","author":"Zeisberg","year":"2006","journal-title":"Mol. Cell Biochem."},{"key":"B132","doi-asserted-by":"publisher","first-page":"12757","DOI":"10.1038\/s41598-019-49287-7","article-title":"A novel technique to prepare a single cell suspension of isolated quiescent human hepatic stellate cells","volume":"9","author":"Zhai","year":"2019","journal-title":"Sci. Rep."},{"key":"B133","doi-asserted-by":"publisher","first-page":"12572","DOI":"10.3390\/ijms232012572","article-title":"The molecular mechanisms of liver fibrosis and its potential therapy in application","volume":"23","author":"Zhang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1435359","DOI":"10.3389\/fphar.2024.1435359","article-title":"Atlas of mildly and highly insoluble matrisome driving liver fibrosis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1567916\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:40:47Z","timestamp":1745991647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1567916\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":136,"alternative-id":["10.3389\/fcell.2025.1567916"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2025.1567916","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"article-number":"1567916"}}